Global Human Rabies Immune Globulin (HRIG) Market Insights, Forecast to 2028

SKU ID : QYR-20327131 | Publishing Date : 25-Feb-2022 | No. of pages : 109

Rabies immunoglobulin is mainly used for passive immunization of patients bitten and scratched by rabies or other animals carrying rabies virus.
Market Analysis and Insights: Global Human Rabies Immune Globulin (HRIG) Market
Due to the COVID-19 pandemic, the global Human Rabies Immune Globulin (HRIG) market size is estimated to be worth US$ 422.6 million in 2022 and is forecast to a readjusted size of US$ 602.2 million by 2028 with a CAGR of 6.1% during the review period. Fully considering the economic change by this health crisis, 200IU accounting for % of the Human Rabies Immune Globulin (HRIG) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Category II Exposure segment is altered to an % CAGR throughout this forecast period.
China Human Rabies Immune Globulin (HRIG) market size is valued at US$ million in 2021, while the US and Europe Human Rabies Immune Globulin (HRIG) are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Human Rabies Immune Globulin (HRIG) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Human Rabies Immune Globulin (HRIG) include CSL Behring, Grifols, Sanofi, Sichuan Yuanda Shuyang, CNBG, Kamada, CBPO, Shuanglin Bio and Weiguang Bio, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Human Rabies Immune Globulin (HRIG) Scope and Segment
Human Rabies Immune Globulin (HRIG) market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Human Rabies Immune Globulin (HRIG) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
200IU
500IU
Segment by Application
Category II Exposure
Category III Exposure
By Company
CSL Behring
Grifols
Sanofi
Sichuan Yuanda Shuyang
CNBG
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai RAAS
Bharat Serum
VINS
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Frequently Asked Questions

This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
  • By product type
  • By End User/Applications
  • By Technology
  • By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
PRICE
4900
9800

7350


  • market Reports market Reports